- |||||||||| CARv3-TEAM-E T cells / Massachusetts General Hospital
Journal: Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. (Pubmed Central) - Mar 13, 2024
P1
Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).
- |||||||||| CARv3-TEAM-E T cells / Massachusetts General Hospital
Enrollment open, Trial completion date, Trial primary completion date: CARv3-TEAM-E T Cells in Glioblastoma (clinicaltrials.gov) - Apr 4, 2023
P1, N=21, Recruiting,
(Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.). Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Jun 2025
- |||||||||| CARv3-TEAM-E T cells / Massachusetts General Hospital
New P1 trial: CARv3-TEAM-E T Cells in Glioblastoma (clinicaltrials.gov) - Dec 21, 2022
P1, N=21, Not yet recruiting,
|
